Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

614
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

592
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
592
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standard modifiable cardiovascular risk factors and acute coronary syndrome free survival.

Atherosclerosis·2026
Same author

Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry.

Journal of clinical medicine·2026
Same author

Pathophysiology, prevention, and management of coronary microvascular obstruction.

European heart journal·2026
Same author

Update on heart transplantation: a clinical consensus statement of the Advanced Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology.

European journal of heart failure·2026
Same author

Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).

ESC heart failure·2026
Same author

Intra-Procedural Three-Dimensional Rotational Angiography in Cryoballoon Ablation of Atrial Fibrillation: An RCT.

Pacing and clinical electrophysiology : PACE·2026
Same journal

Updated analysis of the Bronze Age population genetics from Bezdanjača Cave - the case of I2a1a male individuals.

Croatian medical journal·2026
Same journal

Systemic mesenchymal stem cell therapy for reduction of inflammatory burden in a patient with juvenile-onset rheumatoid arthritis and dialysis-dependent renal failure.

Croatian medical journal·2026
Same journal

Systemic metabolic, hormonal, and glycomic remodeling during a 72-hour fast in healthy adults: a pilot study.

Croatian medical journal·2026
Same journal

Artificial intelligence in pathology: a framework for preserving brain capital in the diagnostic apex.

Croatian medical journal·2026
Same journal

When algorithms testify: artificial intelligence-driven DNA analysis, evidentiary standards, and criminal justice reform.

Croatian medical journal·2026
Same journal

Artificial intelligence enables scale, consistency, and rigor in forensic identity inference.

Croatian medical journal·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Antithrombotics in heart failure.

Davor Miličić, Jure Samardžić1, Mate Petričević

  • 1Jure Samardzic, Department for Cardiovascular Diseases, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia, jure.samardzic@gmail.com.

Croatian Medical Journal
|January 7, 2015
PubMed
Summary
This summary is machine-generated.

Heart failure patients face high risks of thrombosis. While some receive antithrombotic therapy for specific conditions, routine use in all heart failure patients lacks strong evidence, necessitating careful consideration.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Related Experiment Videos

Last Updated: Apr 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K

Area of Science:

  • Cardiology
  • Thrombosis Research
  • Pharmacotherapy

Background:

  • Heart failure (HF) is a prevalent condition with significant morbidity and mortality.
  • HF patients have an elevated risk of arterial and venous thrombosis, leading to adverse events.
  • Current guidelines often recommend antithrombotic therapy for HF patients with specific indications like ischemic heart disease or atrial fibrillation.

Purpose of the Study:

  • To review the existing evidence regarding the use of antithrombotic therapy in patients with heart failure.
  • To evaluate the benefits and risks of routine antithrombotic treatment in the broader heart failure population.

Main Methods:

  • Literature review of clinical trials and observational studies.
  • Analysis of data on thrombotic events, bleeding complications, and overall mortality in heart failure patients receiving antithrombotic agents.

Main Results:

  • Antithrombotic therapy is beneficial for HF patients with established indications (e.g., atrial fibrillation, coronary artery disease).
  • Evidence supporting the routine use of antithrombotic agents in all heart failure patients, irrespective of specific indications, is limited.
  • The risk of bleeding complications must be carefully weighed against the potential benefits.

Conclusions:

  • Antithrombotic therapy should be individualized in heart failure patients based on specific indications and risk assessment.
  • Routine antithrombotic use in all HF patients is not currently supported by robust scientific evidence.
  • Further research is needed to clarify the role of antithrombotic agents in select heart failure populations without traditional indications.